Adherence to Long-Term Therapies - Evidence for Action
(2003; 211 pages) View the PDF document
Table of Contents
View the documentPreface
View the documentAcknowledgements
View the documentScientific writers
View the documentIntroduction
View the documentTake-home messages
Open this folder and view contentsSection I - Setting the scene
Open this folder and view contentsSection II - Improving adherence rates: guidance for countries
Close this folderSection III - Disease-Specific Reviews
Open this folder and view contentsChapter VII - Asthma
Open this folder and view contentsChapter VIII - Cancer (Palliative care)
Open this folder and view contentsChapter IX - Depression
Open this folder and view contentsChapter X - Diabetes
Close this folderChapter XI - Epilepsy
View the document1. Introduction
View the document2. Adherence to epilepsy therapy
View the document3. Epidemiology of adherence
View the document4. Factors affecting adherence and interventions used to improve it
View the document5. Conclusions
View the document6. References
Open this folder and view contentsChapter XII - Human immunodeficiency virus and acquired immunodeficiency syndrome
Open this folder and view contentsChapter XIII - Hypertension
Open this folder and view contentsChapter XIV - Tobacco smoking cessation
Open this folder and view contentsChapter XV - Tuberculosis
Open this folder and view contentsAnnexes
Open this folder and view contentsWhere to find a copy of this book

2. Adherence to epilepsy therapy

Adherence was not usually defined in the published studies, but referred to generally as patients following medical recommendations. Authors generally considered adherence in behavioural terms, whereby the patient had an active and informed role to play in a therapeutic situation (13,20). In this sense, adherence to prescribed medication was seen as a health-promoting behaviour (21).

The types of nonadherence were described as follows: reduced or increased amount of single dose; decreased or increased number of daily doses; extra dosing; incorrect dosing intervals; being unaware of the need for life-long regular medication; taking duplicate medication; taking discontinued medication; discontinuing prescribed medication; regularly forgetting to take medication, and incorrect use of medication (18,20,22).

Medication use was assessed by review of medical records; patient self-report; family report; pill counts; prescription refill rates, and biological markers, including serum, urine and saliva assays to quantify medications or their metabolites (2,11,12,14,23 - 26). The best indicator of adherence is believed to be serum levels of anticonvulsant drugs (18,27). Other methods of monitoring adherence, such as electronic measures are not discussed further here because of the lack of published studies in this area. In several studies, patients whose serum levels were outside the therapeutic range were classified as nonadherent (19,23,28). However, serum levels are not a perfect measure. Although blood levels of anticonvulsant medications can be measured, it is difficult to translate them into comparable measures of adherence for patients on different medications and doses. Furthermore, sub-therapeutic levels of a drug in the serum can be due either to poor compliance or the need for a higher dosage (2). Patients with impaired absorption or rapid or ultra-rapid metabolism can have low serum levels even if their intake of AEDs is regular and according to prescription (11,26,29).

Dowse et al. and Leppik et al. reported that indirect measures such as patient interview, tablet counts and prescription refill records gave no indication of the true amount of the drug present in the body and could be inaccurate or biased (18,19). However, using the measurement of drug concentration in blood alone, except in cases of extremely low adherence and variability of drug intake, is not sufficient to detect incorrect drug intake. Therefore, the use of clinical markers and self-reported adherence should also be considered (11).

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017